Phase III study of Fosravuconazole in the patients with Onychomycosis

Trial Profile

Phase III study of Fosravuconazole in the patients with Onychomycosis

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs Fosravuconazole (Primary)
  • Indications Onychomycosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Satori Pharmaceuticals
  • Most Recent Events

    • 22 Jan 2018 New trial record
    • 19 Jan 2018 According to an Eisai Co Ltd media release, NAILIN Capsules 100mg containing the active ingredient fosravuconazole L-lysine ethanolate (fosravuconazole) has recieved marketing and manufacturing for the treatment of onychomycosis in Japan on January 19, 2018.
    • 19 Jan 2018 According to an Eisai Co Ltd media release, after confirming efficacy and safety in the study, Sato Pharma applied for marketing and manufacturing authorization in January 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top